Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clene Inc. stock logo
CLNN
Clene
$5.76
-1.9%
$6.22
$3.25
$13.50
$75.01M0.91197,743 shs116,337 shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$2.22
-13.6%
$1.69
$0.91
$2.88
$299.56M2.534.36 million shs7.55 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.33
+4.0%
$2.44
$2.04
$7.08
$288.23M1.321.36 million shs809,310 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.92
+1.0%
$3.50
$2.40
$5.45
$315.57M0.482.33 million shs2.84 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clene Inc. stock logo
CLNN
Clene
-1.87%-13.90%-6.19%+8.68%+46.94%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-13.62%-6.33%+45.10%+60.87%+63.24%
Organogenesis stock logo
ORGO
Organogenesis
+4.02%-12.41%-9.34%-19.66%-17.08%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
+1.04%-2.34%-17.98%-37.07%-1.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clene Inc. stock logo
CLNN
Clene
$5.76
-1.9%
$6.22
$3.25
$13.50
$75.01M0.91197,743 shs116,337 shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$2.22
-13.6%
$1.69
$0.91
$2.88
$299.56M2.534.36 million shs7.55 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.33
+4.0%
$2.44
$2.04
$7.08
$288.23M1.321.36 million shs809,310 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.92
+1.0%
$3.50
$2.40
$5.45
$315.57M0.482.33 million shs2.84 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clene Inc. stock logo
CLNN
Clene
-1.87%-13.90%-6.19%+8.68%+46.94%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-13.62%-6.33%+45.10%+60.87%+63.24%
Organogenesis stock logo
ORGO
Organogenesis
+4.02%-12.41%-9.34%-19.66%-17.08%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
+1.04%-2.34%-17.98%-37.07%-1.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clene Inc. stock logo
CLNN
Clene
2.71
Moderate Buy$33.25477.26% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.29
Hold$5.13130.86% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$5.75146.78% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.38
Hold$8.44189.19% Upside

Current Analyst Ratings Breakdown

Latest CLNN, RCKT, FATE, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/1/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UpgradeSell (E+)Sell (D-)
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Set Price Target$3.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Initiated CoverageHold$3.00
5/26/2026
Clene Inc. stock logo
CLNN
Clene
DowngradeSell (D-)Sell (E+)
5/19/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Set Price Target$4.00
5/19/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Initiated CoverageBuy
5/14/2026
Clene Inc. stock logo
CLNN
Clene
Reiterated RatingBuy
5/14/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
DowngradeSell (D-)Sell (E+)
5/13/2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
UpgradeSell (E+)Sell (D-)
5/11/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeHold (C)Sell (D)
5/11/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Reiterated RatingBuy$11.00
(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clene Inc. stock logo
CLNN
Clene
$200K368.06N/AN/A($1.62) per share-3.56
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$6.65M38.91N/AN/A$1.80 per share1.23
Organogenesis stock logo
ORGO
Organogenesis
$564.17M0.53$0.67 per share3.46$2.36 per share0.99
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$2.56 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clene Inc. stock logo
CLNN
Clene
-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$37.03M-$0.19N/AN/AN/A-0.84%9.63%4.76%8/6/2026 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)

Latest CLNN, RCKT, FATE, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Clene Inc. stock logo
CLNN
Clene
-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million
5/13/2026Q1 2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.37-$0.08-$0.44$43.26 million$37.23 million
5/7/2026Q1 2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.41-$0.42-$0.01-$0.42$4.47 millionN/A
3/12/2026Q4 2025
Clene Inc. stock logo
CLNN
Clene
-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clene Inc. stock logo
CLNN
Clene
N/A
1.94
1.93
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
5.85
5.85
Organogenesis stock logo
ORGO
Organogenesis
0.05
3.53
3.16
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.08
6.12
6.12

Institutional Ownership

CompanyInstitutional Ownership
Clene Inc. stock logo
CLNN
Clene
23.28%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%

Insider Ownership

CompanyInsider Ownership
Clene Inc. stock logo
CLNN
Clene
28.30%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.74%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
21.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clene Inc. stock logo
CLNN
Clene
10012.78 million9.16 millionNo Data
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550116.56 million111.03 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million86.21 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240109.19 million85.94 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clene stock logo

Clene NASDAQ:CLNN

$5.76 -0.11 (-1.87%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$5.70 -0.05 (-0.95%)
As of 06/3/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$2.22 -0.35 (-13.62%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$2.21 -0.01 (-0.41%)
As of 06/3/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.33 +0.09 (+4.02%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$2.27 -0.06 (-2.40%)
As of 06/3/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$2.92 +0.03 (+1.04%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$2.90 -0.02 (-0.82%)
As of 06/3/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.